The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of the Pallia 10 score in patients enrolled in phase I trials at Gustave Roussy Cancer Center.
 
Kaissa Ouali
No Relationships to Disclose
 
Christine Mateus
No Relationships to Disclose
 
Ariane Laparra
No Relationships to Disclose
 
Elena Pavliuc
No Relationships to Disclose
 
Patricia Martin Romano
No Relationships to Disclose
 
Anda Sampetrean
No Relationships to Disclose
 
Andrea Varga
No Relationships to Disclose
 
Stéphane Champiat
No Relationships to Disclose
 
Loic Verlingue
No Relationships to Disclose
 
Arthur Geraud
No Relationships to Disclose
 
Aurelien Marabelle
Stock and Other Ownership Interests - Centessa Pharmaceuticals; Centessa Pharmaceuticals (Inst); HiFiBiO Therapeutics; PEGASCY; PEGASCY (Inst); Shattuck Labs
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; Oncovir
Consulting or Advisory Role - AstraZeneca; Centessa Pharmaceuticals; Eisai; HiFiBiO Therapeutics; ImCheck therapeutics; Innate Pharma; Lytix Biopharma; MedinCell; MSD; OSE Immunotherapeutics; Pierre Fabre; Redx Pharma; Roche; SERVIER; Sotio
Speakers' Bureau - BMS
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - monoclonal antibodies against CD81 (Stanford University)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Spectrum Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Anas Gazzah
No Relationships to Disclose
 
Rastilav Bahleda
No Relationships to Disclose
 
Sophie Postel-Vinay
No Relationships to Disclose
 
Vincent Ribrag
No Relationships to Disclose
 
Jean-Charles Soria
Employment - AstraZeneca/MedImmune
Leadership - Hookipa Pharma
Stock and Other Ownership Interests - AstraZeneca; Daiichi Sankyo (I); Gritstone Bio
Honoraria - Relay Therapeutics
 
Florian Scotte
No Relationships to Disclose
 
Christophe Massard
No Relationships to Disclose
 
Capucine Baldini
Expert Testimony - Abbvie; Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Roche/Genentech